Can utilization of clinical pathways (CPs) effectively reduce drug spending (DS) within the Oncology Care Model (OCM)?

Authors

null

Andrew Allan Hertler

New Century Health, Wellesley, MA

Andrew Allan Hertler, Rani Khetarpal, James Lloyd Wade, Ed Bassin, Sang Chau, Vijay Kumar Damarla

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session B: Patient Experience; Safety; Technology and Innovation in Quality of Care

Track

Patient Experience,Technology and Innovation in Quality of Care,Safety

Sub Track

Use of Clinical Pathways

Citation

J Clin Oncol 37, 2019 (suppl 27; abstr 269)

DOI

10.1200/JCO.2019.37.27_suppl.269

Abstract #

269

Poster Bd #

A1

Abstract Disclosures

Similar Posters

First Author: Chetan Vakkalagadda

Poster

2019 ASCO Quality Care Symposium

Pathways impact on OCM drug cost.

Pathways impact on OCM drug cost.

First Author: Valerie Pracilio Csik

Poster

2019 ASCO Quality Care Symposium

Community oncologists' perceptions three years after the Oncology Care Model.

Community oncologists' perceptions three years after the Oncology Care Model.

First Author: Jonathan Karl Kish